Funder
Guangzhou Major Clinical Technology Project
Science and Technology Program of Guangzhou
Natural Science Foundation of Guangdong Province
Publisher
Springer Science and Business Media LLC
Reference3 articles.
1. Huang S, Wang S, Gao Z, et al. Induction immunochemotherapy yields a higher conversion rate 2 and better overall survival than chemotherapy in initially- 3 unresectable esophageal squamous cell carcinoma. Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-024-15458-8.
2. Gao Z, Huang S, Wang S, Tang D, Xu W, Zeng R, et al. Efficacy and safety of immunochemotherapy, immunotherapy, chemotherapy, and targeted therapy as first-line treatment for advanced and metastatic esophageal cancer: a systematic review and network meta-analysis. Lancet Region Health-Western Pac. 2023;38:100841.
3. Liu Z, Zhang Y, Ma N, Yang Y, Ma Y, Wang F, et al. Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma. Cancer Cell [Internet]. 2023 Oct 12 [cited 2023 Oct 17]. Available at: https://www.cell.com/cancer-cell/abstract/S1535-6108(23)00327-6